Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Erasca, Inc. in the United States District Court for the Southern District of California on behalf of purchasers of Erasca common stock between January 14, 2025 and April 26, 2026. The lawsuit alleges that the company made false and misleading statements and failed to disclose that ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines, Inc., placing Erasca at risk of violating patent and trade secret protections. On April 28, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to ERAS-0015, causing the stock to drop 48 percent from $19.15 to $9.90 per share. Investors have until August 10, 2026 to seek lead plaintiff appointment.
Erasca IncClass action lawsuit and patent/trade secret claims against Erasca regarding ERAS-0015, causing 48% stock drop.
Revolution Medicines IncRevolution Medicines is the plaintiff alleging patent infringement and trade secret misappropriation by Erasca.